Edwards Lifesciences' JenaValve Acquisition Blocked by FTC, Raises 2026 EPS Guidance to $3.05
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 10h ago
0mins
Source: Businesswire
- Acquisition Blocked: The U.S. District Court for the District of Columbia granted the FTC's injunction against Edwards Lifesciences' acquisition of JenaValve, preventing the deal despite the company's belief that it would benefit an underserved patient group.
- Market Impact: With the acquisition halted, Edwards will continue to focus on its innovative AR treatment solutions, particularly the SOJOURN transcatheter AR valve, aimed at improving care for heart disease patients.
- Financial Guidance Adjustment: The company has raised its 2026 adjusted EPS guidance to $2.90 to $3.05 from the previous $2.80 to $2.95, reflecting an optimistic outlook for future performance.
- Commitment to Innovation: Edwards Lifesciences remains dedicated to advancing novel therapies and enrolling patients in the JOURNEY pivotal trial, aiming to enhance patient care quality despite the acquisition setback.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
14 Buy
10 Hold
0 Sell
Moderate Buy
Current: 84.580
Low
83.00
Averages
92.95
High
104.00
Current: 84.580
Low
83.00
Averages
92.95
High
104.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
